Under current budget rules, the PBS is unable to grow well into the next decade, so this makes new pricing policies an inevitable consequence of the government's commitment to list every medicine recommended by the PBAC. …
Latest Video
New Stories
-
Clinical trials: Competition across countries and companies
December 13, 2019 - - Latest News -
High in fees low on performance measures
December 13, 2019 - - Latest News -
Deborah Monk: Recollections from APMA to Medicines Australia
December 13, 2019 - - Latest News -
Novartis launches Innovation Prize with a focus on MS
December 13, 2019 - - Latest News -
New leadership for AbbVie Australia
December 12, 2019 - - Latest News -
Key trade agreement scraps pharma IP provision
December 12, 2019 - - Latest News -
Still time to take advantage of BioPharmaDispatch 2020 early registration
December 12, 2019 - - Latest News